Hormonal treatment of postmenopausal women

Academic Article

Abstract

  • To the Editor: In his review of hormonal treatment of postmenopausal women (April 14 issue),1 Dr. Belchetz states (in Table 4) that “Combination therapy is contraindicated in women with hyperlipidemia or established ischemic heart disease.” What is the basis for this surprising statement? Although there has been concern that the addition of a progestin to estrogen-replacement therapy may attenuate the beneficial effects of estrogen on the lipid profile, the results of two recent, large cross-sectional studies2,3 suggest that the combination is associated with an equally favorable or more favorable profile of serum lipids and other risk factors, as compared. © 1994, Massachusetts Medical Society. All rights reserved.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Bittner V; Belchetz PE
  • Start Page

  • 550
  • Volume

  • 331
  • Issue

  • 8